BNTX

BioNTech has officially named its next CEO. The transition appears carefully planned, not reactive.

BioNTech NASDAQ: BNTX reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt out of a shingles vaccine development program.

Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.

German vaccine maker ​BioNTech lowered its ‌full year sales outlook range on ​Tuesday due ​to softer-than-expected COVID-19 ⁠vaccine demand and ​the timing ​of milestone-related revenues.

Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer , taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple milestones achieved in 2026, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan ; upcoming 2026 catalysts include three late-stage readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies Pumitamig in combination with chemotherapy showed encouraging efficacy in first line non-small cell lung cancer and results presented at 2026 ASCO Annual Meeting became the third global pumitamig data set consistently showing efficacy across PD-L1 expression levels Approval received for new variant-adapted COVID-19 vaccine by the European Commission ; further launch preparation underway as recommended by regulators Second quarter 2026 revenues of €105.6 million1 , adjusted2 R&D expenses of €477.1 million (IFRS R&D expenses of €551.0 million), and adjusted SG&A 3 expenses of €197.8 million Revising full year 2026 financial guidance range for revenues to €1.6–1.9 billion, adjusted R&D expenses to €2.0–2.3 billion, and maintaining adjusted SG&A expenses of €700–800 million Maintained strong financial position with cash, cash equivalents and security investments of €16.6 billion 4 Conference call and webcast scheduled for August 4, 2026, at 8:00 a.m.

German biotech ​firm BioNTech said ‌on Monday that Sobi's CEO Guido Oelkers will ​succeed Ugur ​Sahin as its chief executive.

Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer (“CEO”), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, “Sobi”), where he has served as CEO since 2017.

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season's vaccine    NEW YORK and MAINZ, GERMANY, July 29, 2026 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies' 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season.

MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

BioNTech has held confidential talks with potential buyers about ​the German sites that the ‌COVID‑19 vaccine maker plans to close, which has now grown to four locations, ​the Handelsblatt newspaper reported on ​Friday.